designed a nanotheranostic system with dual targeting and ROS response for intracranial glioblastoma treatment (Figure 13C,D).[173] This nanotheranostic system is consisting of several components including poly[(2‐acryloyl)ethyl(p‐boronic acid benzyl)diethylammonium bromide] (BA‐PDEAEA, BAP), zwitterionic lipid distearoyl phosphoethanol‐aminepolycarboxybetaine (DSPE‐PCB), cholesterol, angiopep‐2, temozolomide (TMZ), TGF‐β siRNA, and SPIONs, termed as (Ang‐LiB(T+AN@siTGF‐β), ALBTA). Here, TGFB1 is linked to glioblastoma.